Ładuje się......
Immune-related adverse events of immune checkpoint inhibitors: a brief review
Immune checkpoint inhibitors (icis) such as inhibitors of ctla-4, PD-1, and PD-L1, given as monotherapy or combination therapy have emerged as effective treatment options for immune-sensitive solid tumours and hematologic malignancies. The benefits of icis can be offset by immune-related adverse eve...
Zapisane w:
| Wydane w: | Curr Oncol |
|---|---|
| 1. autor: | |
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
Multimed Inc.
2018
|
| Hasła przedmiotowe: | |
| Dostęp online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6209551/ https://ncbi.nlm.nih.gov/pubmed/30464684 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3747/co.25.4235 |
| Etykiety: |
Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!
|